Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 3 2Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Carboplatin 98Cisplatin 95pembrolizumab 91Gemcitabine 81Paclitaxel 79Docetaxel 70Capecitabine 64Oxaliplatin 53Fluorouracil 51Specimen Handling 50Magnetic Resonance Spectroscopy 49Bevacizumab 49Radiotherapy 48Dexamethasone 45Cyclophosphamide 45Drug Therapy 39Leucovorin 38Doxorubicin 37Pemetrexed 35Irinotecan 34Injections 30Rituximab 29Vincristine 28Trastuzumab 26Radiosurgery 26Prednisone 26Lenalidomide 25Etoposide 25130-nm albumin-bound paclitaxel 25Radiation 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × neratinib × Clear all
NCT05615818 2026-05-19

SAFIR-ABC10

UNICANCER

Phase 3 Recruiting
800 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT05760612 2025-09-25

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Recruiting
300 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡